====== John Conly ======

{{ :public_health_agencies:canada:john_conly-01.png?200|}}

Dr. **John Conly**, MD, CM, CCFP, FRCPC, FCAHS, FAMMI, FACP, FSHEA, FIDSA, is a specialist in infectious diseases in Alberta, Canada.
===== Affiliations =====

==== Alberta Health Services ====

Conly is an Infectious Disease / IPC Expert for the [[AHS COVID-19 Scientific Advisory Group]] under [[Alberta Health Services]].((//2019-nCoV Scientific Advisory Group.// (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf))

==== Alberta Medical Association ====

Conly received the Medal for Distinguished Service from the [[:Alberta Medical Association]] for "outstanding personal contributions to the medical profession".

==== AMR One Health Consortium ====

Conly is a Work Package Lead, Principal Investigator, and Executive Committee member of the [[:AMR One Health Consortium|Antimicrobial Resistance (AMR) One Health Consortium]].

==== Canadian Committee on Antibiotic Resistance ====

Conly served as Chairman of the Board for the [[:Canadian Committee on Antibiotic Resistance]] (CCAR).

==== Canadian Expert Advisory Group on Antimicrobial Resistance ====

Conly is a member of the [[:Canadian Expert Advisory Group on Antimicrobial Resistance]] (CEAGAR). Fellow members include [[:Allison McGeer]], [[:Scott Weese]], and [[:Andrew Morris]].((//Expert Advisory Group on Antimicrobial Resistance (EAGAR) - Membership.// (2021, June 11). Government of Canada. https://archive.ph/T5QcZ))
==== Canadian Expert Drug Advisory Committee ====

Conly served as Vice Chair of the [[:Canadian Expert Drug Advisory Committee]] (CEDAC).

==== Canadian Infectious Disease Society ====

Conly formerly served as President of the [[:Canadian Infectious Disease Society]] (CIDS).

==== University of Calgary ====

Conly is a Professor of Medicine, Microbiology, Immunology & Infectious Diseases, Pathology & Laboratory Medicine in the Department of Medicine (Infectious Diseases), Cumming School of Medicine, [[:University of Calgary]], where he is also the former Head of the Department of Medicine.((//John Conly.// University of Calgary. Retrieved January 8, 2022, from https://research.ucalgary.ca/amr/people/investigators/john-conly))

=== Snyder Institute for Chronic Diseases ===

Conly is the former Co-Director for the [[:Snyder Institute for Chronic Diseases]] at the University of Calgary.

==== W21C ====

Conly is the Medical Director of [[:W21C]], a research and innovation initiative based in the [[:University of Calgary]] and the Calgary Zone of [[Alberta Health Services]] (AHS).((//Dr. John Conly, CM, MD.// W21C. Retrieved January 8, 2022, from https://archive.ph/Go60B)) ((//About.// W21C. Retrieved January 8, 2022, from https://archive.ph/1DFCp))

It is funded by the [[:Government of Canada]] through a [[:Western Economic Partnership Agreement]] (WEPA), and later received funding from [[:Alberta Health and Wellness]] (AH&W), [[:Alberta Innovates]], [[:Alberta Ministry of Jobs, Economy, and Innovation]], [[:Western Economic Diversification Canada]], and [[:Innovate Calgary]].

==== World Health Organization ====

Conly is a member of the [[:World Health Organization]] Advisory Group on Integrated Surveillance of Antimicrobial Resistance. He is overseeing the Calgary study site of the WHO's "Case-control study to assess risk factors for SARS-CoV-2 infection among healthcare workers" under the [[:UNITY Studies]] project.((//Early investigations protocols.// World Health Organization. Retrieved January 9, 2022, from https://archive.ph/5vFGC))

===== Relationships with Pharmaceutical Companies =====

  * Conly has received funding from [[:pharmaceutical_companies:Pfizer]] via the [[:University of Calgary]] to conduct its STRIVE //S. aureus// vaccine randomized clinical trial((McCubbin, K. D., Anholt, R. M., de Jong, E., Ida, J. A., Nóbrega, D. B., Kastelic, J. P., Conly, J. M., Götte, M., McAllister, T. A., Orsel, K., Lewis, I., Jackson, L., Plastow, G., Wieden, H.-J., McCoy, K., Leslie, M., Robinson, J. L., Hardcastle, L., Hollis, A., & Ashbolt, N. J. (2021). //Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada.// Frontiers in Public Health, 9. https://doi.org/10.3389/fpubh.2021.726484))
  * He previously received speakers fees from [[:pharmaceutical_companies:Janssen]], [[:pharmaceutical_companies:Pfizer]], and [[:pharmaceutical_companies:Astellas]].((Conly, J. M. (2012). //Antimicrobial resistance programs in Canada 1995-2010: a critical evaluation.// Antimicrobial Resistance and Infection Control, 1(1), 10. https://doi.org/10.1186/2047-2994-1-10))